These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1561523)

  • 1. Gallbladder function in acromegalic patients taking long-term octreotide: evidence of rebound hypermotility on cessation of treatment.
    Rhodes M; James RA; Bird M; Clayton B; Kendall-Taylor P; Lennard TW
    Scand J Gastroenterol; 1992; 27(2):115-8. PubMed ID: 1561523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones.
    Hussaini SH; Pereira SP; Veysey MJ; Kennedy C; Jenkins P; Murphy GM; Wass JA; Dowling RH
    Gut; 1996 May; 38(5):775-83. PubMed ID: 8707128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR.
    Moschetta A; Stolk MF; Rehfeld JF; Portincasa P; Slee PH; Koppeschaar HP; Van Erpecum KJ; Vanberge-Henegouwen GP
    Aliment Pharmacol Ther; 2001 Feb; 15(2):181-5. PubMed ID: 11148435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of gallbladder contractility after withdrawal of long-term octreotide therapy in acromegalic patients.
    Shi YF; Zhu XF; Harris AG; Zhang JX; Deng JY
    Acta Endocrinol (Copenh); 1993 Sep; 129(3):207-12. PubMed ID: 8212985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of long term octreotide on gall stone formation and gall bladder function.
    Bigg-Wither GW; Ho KK; Grunstein RR; Sullivan CE; Doust BD
    BMJ; 1992 Jun; 304(6842):1611-2. PubMed ID: 1628089
    [No Abstract]   [Full Text] [Related]  

  • 6. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management.
    Redfern JS; Fortuner WJ
    Am J Gastroenterol; 1995 Jul; 90(7):1042-52. PubMed ID: 7611194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly.
    Turner HE; Lindsell DR; Vadivale A; Thillainayagam AV; Wass JA
    Eur J Endocrinol; 1999 Dec; 141(6):590-4. PubMed ID: 10601961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly.
    Catnach SM; Anderson JV; Fairclough PD; Trembath RC; Wilson PA; Parker E; Besser GM; Wass JA
    Gut; 1993 Feb; 34(2):270-3. PubMed ID: 8432484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholelithiasis and acromegaly: therapeutic strategies.
    Montini M; Gianola D; Pagani MD; Pedroncelli A; Caldara R; Gherardi F; Bonelli M; Lancranjan I; Pagani G
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):401-6. PubMed ID: 8187305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.
    Shi YF; Zhu XF; Harris AG; Zhang JX; Dai Q
    J Clin Endocrinol Metab; 1993 Jan; 76(1):32-7. PubMed ID: 8421099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gallstones during octreotide therapy.
    Dowling RH; Hussaini SH; Murphy GM; Besser GM; Wass JA
    Metabolism; 1992 Sep; 41(9 Suppl 2):22-33. PubMed ID: 1355588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients.
    Tauber JP; Poncet MF; Harris AG; Barthel HR; Simonetta-Chateauneuf C; Buscail L; Bayard F
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3262-6. PubMed ID: 7593435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postprandial gallbladder motility and plasma cholecystokinin at regular time intervals after injection of octreotide in acromegalics on long-term treatment.
    Hopman WP; Van Liessum PA; Pieters GF; Jansen JB; Lamers CB; Smals AG; Rosenbusch G; Kloppenborg PW
    Dig Dis Sci; 1992 Nov; 37(11):1685-90. PubMed ID: 1425066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
    Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gall stones induced by octreotide.
    Catnach SM; Wass JA; Anderson JV; Besser M; Fairclough P; Hussaini H; Dowling H
    BMJ; 1992 Aug; 305(6848):313. PubMed ID: 1392873
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prospective study of functional changes in the gallbladder and formation of gallstones induced by long-term treatment of somatostatin analogue SMS201-995 in patients of active acromegaly].
    Zhu XF; Shi YF; Zhang JX
    Zhonghua Nei Ke Za Zhi; 1991 Jul; 30(7):405-8, 455. PubMed ID: 1752152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cisapride on gall bladder emptying, intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial.
    Veysey MJ; Malcolm P; Mallet AI; Jenkins PJ; Besser GM; Murphy GM; Dowling RH
    Gut; 2001 Dec; 49(6):828-34. PubMed ID: 11709518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proceedings of the discussion: 'Tolerability and safety of Sandostatin'.
    Popovic V; Chayvialle JA; Wass JA
    Digestion; 1993; 54 Suppl 1():104-6. PubMed ID: 8359564
    [No Abstract]   [Full Text] [Related]  

  • 19. Gallstones during octreotide therapy.
    Dowling RH; Hussaini SH; Murphy GM; Wass JA
    Digestion; 1993; 54 Suppl 1():107-20. PubMed ID: 8103009
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of octreotide on fasting gall bladder emptying, antroduodenal motility, and motilin release in acromegaly.
    Stolk MF; van Erpecum KJ; Koppeschaar HP; Samsom M; Smout AJ; Akkermans LM; Peeters TL; vanBerge-Henegouwen GP
    Gut; 1995 May; 36(5):755-60. PubMed ID: 7797127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.